Search research articles
Contact Us
Filters
Showing results (1011-1020 of 1,033) with videos related to
Page
of 104
Sort By:
JHEP Reports : Innovation in Hepatology
|
January 4, 2021
Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2
Masatoshi Kudo, Peter R Galle, Giovanni Brandi, et al.
Science Immunology
|
June 30, 2023
Polymorphic KIR3DL3 expression modulates tissue-resident and innate-like T cells
William H Palmer, Laura Ann Leaton, Ana Campos Codo, et al.
Neurourology and Urodynamics
|
March 3, 2020
Applying concepts of life course theory and life course epidemiology to the study of bladder health and lower urinary tract symptoms among girls and women
Sonya S Brady, Amanda Berry, Deepa R Camenga, et al.
Gut
|
September 15, 2022
GATA4 and GATA6 loss-of-expression is associated with extinction of the classical programme and poor outcome in pancreatic ductal adenocarcinoma
Mónica P de Andrés, Richard J Jackson, Irene Felipe, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 22, 2022
Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study
John Bridgewater, Peter Fletcher, Daniel H Palmer, et al.
HLA
|
October 18, 2023
HLA-DPB1*13:01 associates with enhanced, and KIR2DS4*001 with diminished protection from developing severe COVID-19
Ticiana D J Farias, Silvia Brugiapaglia, Susanna Croci, et al.
JAMA
|
July 12, 2012
Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial
John P Neoptolemos, Malcolm J Moore, Trevor F Cox, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 14, 2022
Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial
Gontran Verset, Ivan Borbath, Mark Karwal, et al.
Journal of Hepatology
|
February 20, 2025
A phase III randomized study of first-line NUC-1031/cisplatin vs. gemcitabine/cisplatin in advanced biliary tract cancer
Jennifer J Knox, Mairéad G McNamara, Igor S Bazin, et al.
Cancers
|
November 27, 2021
hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA
Karen Aughton, Nils O Elander, Anthony Evans, et al.
Page
of 104
Search research articles
Search
Showing results (1011-1020 of 1,033) with videos related to
Sort By:
Page
of 104
JHEP Reports : Innovation in Hepatology
|
January 4, 2021
Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2
Masatoshi Kudo, Peter R Galle, Giovanni Brandi, et al.
Science Immunology
|
June 30, 2023
Polymorphic KIR3DL3 expression modulates tissue-resident and innate-like T cells
William H Palmer, Laura Ann Leaton, Ana Campos Codo, et al.
Neurourology and Urodynamics
|
March 3, 2020
Applying concepts of life course theory and life course epidemiology to the study of bladder health and lower urinary tract symptoms among girls and women
Sonya S Brady, Amanda Berry, Deepa R Camenga, et al.
Gut
|
September 15, 2022
GATA4 and GATA6 loss-of-expression is associated with extinction of the classical programme and poor outcome in pancreatic ductal adenocarcinoma
Mónica P de Andrés, Richard J Jackson, Irene Felipe, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 22, 2022
Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study
John Bridgewater, Peter Fletcher, Daniel H Palmer, et al.
HLA
|
October 18, 2023
HLA-DPB1*13:01 associates with enhanced, and KIR2DS4*001 with diminished protection from developing severe COVID-19
Ticiana D J Farias, Silvia Brugiapaglia, Susanna Croci, et al.
JAMA
|
July 12, 2012
Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial
John P Neoptolemos, Malcolm J Moore, Trevor F Cox, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 14, 2022
Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial
Gontran Verset, Ivan Borbath, Mark Karwal, et al.
Journal of Hepatology
|
February 20, 2025
A phase III randomized study of first-line NUC-1031/cisplatin vs. gemcitabine/cisplatin in advanced biliary tract cancer
Jennifer J Knox, Mairéad G McNamara, Igor S Bazin, et al.
Cancers
|
November 27, 2021
hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA
Karen Aughton, Nils O Elander, Anthony Evans, et al.
Page
of 104